Cureus . The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids

[tetano]

Cureus


. 2022 Feb 25;14(2):e22614.
doi: 10.7759/cureus.22614. eCollection 2022 Feb.
The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids


Vijairam Selvaraj ¹ , Arkadiy Finn ² , Jennifer Li ³ , Kwame Dapaah-Afriyie ²



Affiliations

• PMID: 35371682
• PMCID: PMC8958274
• DOI: 10.7759/cureus.22614

Abstract

Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.

Keywords: chis; covid; covid19; covid19 purgatory syndrome; cps; hyperinflammation; hyperinflammatory syndrome; mis-a; sars-cov-2; sars-cov2.